Fragile X Syndrome – Drugs In Development, 2024
Powered by ![]()
Unlock hidden opportunities in the Pharmaceuticals industry
Empower your strategies with our Fragile X Syndrome – Drugs In Development, 2024 report and make more profitable business decisions.
Fragile X syndrome is a genetic condition that causes a range of developmental problems including learning disabilities and cognitive impairment. Fragile X syndrome is caused by a change in a gene called FMR1, and occurs both in males and females. Symptoms include delay in crawling, walking, or twisting; hyperactive or impulsive behavior; speech and language delay; and intellectual disability.
The Fragile X Syndrome drugs in development market research report provide comprehensive information on the therapeutics under development for Fragile X Syndrome, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action and product description of the therapeutics, and the latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Fragile X Syndrome and features dormant and discontinued products.
Note:
* This is an “on-demand” report and will be delivered within 2 business days (excluding weekends and holidays) of the purchase.
* Certain sections in the report may be removed or altered based on the availability and relevance of data.
| Quick View – Fragile X Syndrome | Key Targets |
|
|
| Key Mechanisms of Action |
|
||
| Key Routes of Administration |
|
||
| Key Molecule Types |
|
||
| Major Companies |
|
||
Scope
- Therapeutics in Development: Covering 63 molecules, with 59 developed by companies and the rest by universities/institutes.
- Analysis Parameters: Offering insights by stage of development, drug target, MoA, RoA, and molecule type for a comprehensive overview.
- Pharmacological Insights: Understand the descriptive pharmacological action of therapeutics.
- Development History: Access the complete research and development history.
- Latest News and Press Releases: Stay updated with the latest developments through comprehensive news coverage.
Reasons to Buy
- Holistic insights: Understand the broad spectrum of Fragile X Syndrome therapeutics, aiding strategic decision-making with insights into stages, targets, MoA, RoA and molecule types.
- Pipeline Exploration: Explore the detailed Fragile X Syndrome pipeline, offering nuanced analysis of drug targets, mechanisms of action and routes of administration for varied decision-making.
- Comprehensive R&D: Access thorough R&D histories, providing a comprehensive understanding of Fragile X Syndrome treatments for adaptable decision-making.
- Save valuable hours: Identify key players steering innovation in therapeutics, enabling strategic partnerships.
Key Players
Acadia Pharmaceuticals IncAdvantx Pharmaceuticals Inc
Aelis Farma SAS
Allos Pharma Inc
Anavex Life Sciences Corp
Anima Biotech Inc
Astellas Pharma Inc
Astrogen Ltd
Autifony Therapeutics Ltd
Avekshan LLC
Baergic Bio Inc
Biomed Industries Inc
Centre National de la Recherche Scientifique
Children's Hospital of Philadelphia
Connecta Therapeutics SL
DRI Biosciences Corp
Epigen Biosciences Inc
Forge Biologics Inc
GEXVal Inc
GSK plc
Halucenex Life Sciences Inc
Healx Ltd
Hua Medicine Shanghai Ltd
Jazz Pharmaceuticals Plc
Kantify
Lenire Biosciences Inc
Lysogene SAS
Marvel Biotechnology Inc
Neuren Pharmaceuticals Ltd
Neurochlore
NeuroNascent Inc
Neuroventi Co Ltd
Nova Mentis BioTech Corp
Novartis AG
Paxmedica Inc
Prilenia Therapeutics Development Ltd
Prime Medicine Inc
Prous Institute for Biomedical Research SA
Puretech Health Plc
Quris Technologies Ltd
Recursion Pharmaceuticals Inc
RespireRx Pharmaceuticals Inc
Sentinel Oncology Ltd
Takeda Pharmaceutical Co Ltd
Taysha Gene Therapies Inc
Tetra Therapeutics
Triplet Therapeutics Inc
University of Calgary
Unravel Biosciences
Yale University School of Medicine
Zynerba Pharmaceuticals Inc
Table of Contents
Table
Figures
Frequently asked questions
Related reports
View more Fragile X Syndrome reports